CP
CDTX

Castleview Partners’s Cidara Therapeutics CDTX Stock Holding History

Castleview Partners’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-349
Closed -$5.5K – 754
2021
Q4 		$5.5K Buy
+349
New +$10.9K 0.04% 150

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return

Castleview Partners's CDTX Position: Q1 2022 in Review

Castleview Partners sold out of Cidara Therapeutics (CDTX) in Q1 2022, closing a stake of 349 shares — an estimated $5.5K sold.

Castleview Partners first reported a position in CDTX in Q4 2021 and held it in 1 quarter. The position peaked at $5.5K in Q4 2021. 44 funds tracked by Wall St. Rank hold CDTX as of Q1 2022.

  • Castleview Partners reported no remaining Cidara Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Castleview Partners sold 349 Cidara Therapeutics shares in Q1 2022, an estimated $5.5K.
  • Castleview Partners first reported a position in Cidara Therapeutics in Q4 2021 and held it in 1 quarter.
  • Castleview Partners's Cidara Therapeutics position peaked at $5.5K in Q4 2021.
  • 44 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2022.

Based on Castleview Partners's 13F filing for Q1 2022, filed 16 May 2022.